Compare RGNX & TIPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RGNX | TIPT |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 793.5M | 672.9M |
| IPO Year | 2015 | 2017 |
| Metric | RGNX | TIPT |
|---|---|---|
| Price | $8.05 | $17.55 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $28.75 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 155.0K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 1.40% |
| EPS Growth | ★ 18.08 | N/A |
| EPS | N/A | ★ 0.34 |
| Revenue | ★ $10,393,000.00 | $488,000.00 |
| Revenue This Year | $51.21 | N/A |
| Revenue Next Year | $19.08 | N/A |
| P/E Ratio | ★ N/A | $51.59 |
| Revenue Growth | ★ 126.48 | N/A |
| 52 Week Low | $5.46 | $15.49 |
| 52 Week High | $16.19 | $27.38 |
| Indicator | RGNX | TIPT |
|---|---|---|
| Relative Strength Index (RSI) | 37.32 | 39.34 |
| Support Level | $7.82 | $17.32 |
| Resistance Level | $9.67 | $18.72 |
| Average True Range (ATR) | 0.44 | 0.29 |
| MACD | -0.07 | -0.09 |
| Stochastic Oscillator | 20.47 | 16.85 |
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
Tiptree Inc is a United States-based company that provides specialty insurance products and related services. It has two reportable segments: Insurance and Mortgage. The company generates the majority of its revenue from the Insurance Segment, which is engaged in designing, marketing, and underwriting specialty property and casualty insurance products incorporating value-added coverages and services for select target markets or niches. The Mortgage segment originates loans for sale to institutional investors, including GSEs and FHA/VA, and services loans on behalf of Fannie Mae, Freddie Mac, and Ginnie Mae.